Skip to main content

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Continues to Increase Awareness of Novel Psychedelic Drug Candidates

  • Pharmaceutical company Tryp Therapeutics is preparing for clinical trials evaluating synthetic formulations of psilocybin to treat medical conditions with underpinning neurological causes
  • The clinical trials planned are being conducted in partnership with research teams at the University of Florida and the University of Michigan
  • Tryp executives have been meeting with investors at select conferences recently to increase awareness, including the just-completed Sept. 21 presentation at Oppenheimer’s Fall Healthcare Life Sciences & MedTech Summit
  • The company expects to initiate Phase 2a trials to begin before the end of the year for treating certain eating disorders, with Phase 2b trials to follow next year

Novel pharmaceutical company Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) continues to garner attention for its development of psilocybin as potential treatments for medical conditions with largely unmet needs, presenting an overview of its business and ongoing clinical trials for its two trademarked drug candidates most recently at the Oppenheimer Fall Healthcare Summit.

Tryp is nearing the launch of a Phase 2a clinical trial that aims to establish the value of its psychedelic drug candidate, TRP-8802, in treating chronic and severe eating disorders such as…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.